Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added C-terminal Pro-Gly-Pro extension for stability. It is studied as a neuro-research tool, and its proposed mechanism is examined in cultured neural cells and rodent model systems rather than in any applied context.
Proposed neuromodulatory activity
In model systems Semax is examined for neurotrophic and neuromodulatory signaling. A central line of research interest concerns its proposed influence on brain-derived neurotrophic factor (BDNF) and related neurotrophin pathways, which are widely studied markers of neural plasticity in cell and animal models. Its ACTH-fragment origin distinguishes its mechanism from the melanocortin-receptor agonists elsewhere in this library, even though both trace to the melanocortin/ACTH family.
Neurotrophin-related readouts
Studies frequently measure expression of neurotrophic factors and their downstream signaling in model neural preparations. These readouts are used to characterize how the peptide behaves under controlled conditions, not to infer effects in living subjects.
Melanocortin-system context
Because the core derives from ACTH, some research also considers the peptide in the context of melanocortin-related signaling, distinguishing its fragment-based profile from full ACTH's endocrine activity. This framing helps place Semax relative to other peptides sharing the same parent hormone family.
Stability by design
The Pro-Gly-Pro C-terminal extension is proposed to slow enzymatic breakdown, extending the peptide's usable window in research and making reproducible experiments feasible. Semax is frequently studied alongside the related regulatory peptide Selank, and its sequence design follows general amino acid sequence principles.
Interpreting results
In-vitro concentrations are set by assay design, not human dosing, and proposed neurotrophic effects require careful controls to separate signal from baseline variability. Foundational context is in the Semax overview, with identity confirmation via a COA.
No single confirmed receptor model
Semax is often discussed through downstream expression and signaling changes rather than a single, universally accepted high-affinity receptor. That distinction matters: an increase in a neurotrophin-related marker may indicate pathway modulation, but it does not identify the peptide’s first molecular contact. Mechanistic clarification requires binding studies, receptor perturbation, temporal ordering of early and late responses, and comparison with inactive or scrambled sequences. Metabolites of the short peptide may also contribute to measured effects in some preparations, adding another variable. For now, the most defensible account is a multi-pathway hypothesis supported by model-dependent readouts, with the initiating target still incompletely defined.
Product page: Semax research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.